Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van Sells 2,811 Shares

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) CFO Houte Hans Van sold 2,811 shares of the firm's stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $55,798.35. Following the completion of the sale, the chief financial officer now owns 39,549 shares in the company, valued at approximately $785,047.65. The trade was a 6.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Houte Hans Van also recently made the following trade(s):

• On Friday, November 1st, Houte Hans Van sold 3,546 shares of Nurix Therapeutics stock. The shares were sold at an average price of $24.28, for a total value of $86,096.88.

Nurix Therapeutics Trading Down 3.1 %

Shares of NRIX stock traded down $0.60 on Monday, reaching $19.11. The company had a trading volume of 324,693 shares, compared to its average volume of 650,943. The company has a 50-day moving average of $20.05 and a 200-day moving average of $22.37. Nurix Therapeutics, Inc. has a 12 month low of $7.92 and a 12 month high of $29.56. The stock has a market cap of $1.45 billion, a PE ratio of -6.59 and a beta of 2.14.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. Sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -2.92 earnings per share for the current year.

Institutional Trading of Nurix Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP raised its holdings in shares of Nurix Therapeutics by 8.8% in the 3rd quarter. Wellington Management Group LLP now owns 3,482,105 shares of the company's stock valued at $78,243,000 after purchasing an additional 280,240 shares during the period. Geode Capital Management LLC lifted its position in shares of Nurix Therapeutics by 9.6% in the third quarter. Geode Capital Management LLC now owns 1,448,040 shares of the company's stock valued at $32,544,000 after buying an additional 126,306 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Nurix Therapeutics by 42.7% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company's stock worth $14,869,000 after acquiring an additional 235,971 shares during the period. Millennium Management LLC increased its holdings in shares of Nurix Therapeutics by 60.2% during the 2nd quarter. Millennium Management LLC now owns 599,623 shares of the company's stock worth $12,514,000 after acquiring an additional 225,374 shares during the last quarter. Finally, FMR LLC raised its stake in Nurix Therapeutics by 675.9% in the 3rd quarter. FMR LLC now owns 586,902 shares of the company's stock valued at $13,188,000 after acquiring an additional 511,256 shares during the period.

Analysts Set New Price Targets

Several analysts have recently weighed in on NRIX shares. UBS Group started coverage on shares of Nurix Therapeutics in a research report on Thursday, October 24th. They set a "buy" rating and a $35.00 target price on the stock. Jefferies Financial Group assumed coverage on Nurix Therapeutics in a report on Friday, October 11th. They issued a "buy" rating and a $41.00 target price on the stock. Stifel Nicolaus lifted their price target on Nurix Therapeutics from $34.00 to $36.00 and gave the company a "buy" rating in a report on Wednesday, January 29th. JPMorgan Chase & Co. decreased their price objective on shares of Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating on the stock in a report on Wednesday, January 29th. Finally, Needham & Company LLC dropped their target price on shares of Nurix Therapeutics from $29.00 to $28.00 and set a "buy" rating for the company in a research note on Wednesday, January 29th. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $31.12.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.